Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1 8Phase 3 5Phase 1/2 4Phase 4 1Phase 2/3 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Prostatic Neoplasms 2Neoplasms 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Lymphadenopathy 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × XRP6258 × Clear all
NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

OHSU Knight Cancer Institute

Phase 1/2 Active not recruiting
37 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT01505868 2021-07-30

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
170 enrolled 22 charts
Genitourinary

Lymphadenopathy, Prostatic Neoplasms

NCT01751308 2016-08-12

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

Sanofi

Phase 1/2 Completed
39 enrolled 18 charts
Other solid neoplasm

Malignant Solid Tumor - Malignant Nervous System Neoplasm

NCT01001221 2013-09-11

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Sanofi

Phase 1/2 Terminated
19 enrolled 55 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡